Clinical Trials Logo

Mania clinical trials

View clinical trials related to Mania.

Filter by:

NCT ID: NCT03573297 Completed - Depression Clinical Trials

A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features

Start date: June 15, 2018
Phase: Phase 3
Study type: Interventional

1) To evaluate the efficacy and safety of cariprazine at a target dose of 3.0 mg/day compared with placebo in prevention of relapse in patients with bipolar I disorder whose current episode (i.e. index episode) is manic or depressive, with or without mixed features; 2) To evaluate the efficacy and safety of cariprazine at a target dose of 1.5 mg/day compared with placebo in prevention of relapse in patients with bipolar I disorder whose current episode (i.e. index episode) is manic or depressive, with or without mixed features who were initially stabilized on a target dose of 3.0 mg/day

NCT ID: NCT03383874 Recruiting - Mania (Neurotic) Clinical Trials

A Probiotic Intervention to Prevent Relapse Following Hospitalization for Mania

Start date: September 6, 2018
Phase: Phase 2
Study type: Interventional

This will be a 24-week, randomized, double-blind, placebo-controlled trial of adjunctive probiotic therapy in 66 persons hospitalized with a manic or mixed episode. The active study compound will consist of capsules containing approximately 10^9 colony forming units of the probiotic organisms, Lactobacillus GG and Bifidobacteria lactis strain Bb12. The dose has been selected because it has been used safely in other probiotic trials, was well-tolerated by the participants in two previous trials of individuals with schizophrenia or mania, and was utilized in the original trial on which this replication is based. This dose is higher than that available in most commercially-sold health food supplements. Following hospital discharge, participants will be randomized to receive adjunctive probiotic or placebo for a 24 week period. It is anticipated that of the 66 participants randomized, ~50 (75%) will complete the full 24 weeks of the study. The primary outcome is relapse, defined as re-hospitalization (e.g., admission to an inpatient unit) for psychiatric symptoms following a previous hospital discharge by at least 2 weeks. The occurrence of new mood episodes, the severity of psychiatric symptoms, and any changes in cognitive test scores over the course of the study will also be evaluated. Changes in the levels of inflammatory markers as well as changes in gut microbiota will be evaluated at three time intervals over the course of the study.

NCT ID: NCT02360267 Enrolling by invitation - Depression Clinical Trials

Pediatric Bipolar Registry

PBR
Start date: May 2013
Phase:
Study type: Observational [Patient Registry]

The goal of the Pediatric Bipolar Registry (PBR) is to provide a comprehensive assessment regarding the diagnosis and treatment of pediatric bipolar disorder to children and adolescents with any current mood state and/or children/adolescents who are offspring of a parent with bipolar disorder (BD) type I or II and their families.

NCT ID: NCT01932541 Withdrawn - Bipolar Disorder Clinical Trials

Open-Label Study of Latuda for the Treatment of Mania in Children and Adolescents 6-17 Years Old

Start date: January 2017
Phase: Phase 4
Study type: Interventional

This study is an 8-week open-label trial testing Lurasidone (Latuda®) as a treatment for mania in children and adolescents with Bipolar I, Bipolar II, and Bipolar Spectrum disorders. We hypothesize that Lurasidone will be safe, tolerable, and effective in improving the core symptoms of bipolar disorders in children and adolescents ages 6-17.

NCT ID: NCT01818622 Completed - Bipolar Disorder Clinical Trials

Virtual Darkness as Additive Treatment in Mania

VATMAN
Start date: February 2012
Phase: N/A
Study type: Interventional

In this randomized controlled study we will investigate the effect of blue-blocking goggles or screens (virtual darkness therapy) on manic symptoms in bipolar disorder compared to placebo. This 3-armed study includes 2 patient-groups and a non-bipolar control-group. The main hypothesis is that virtual darkness therapy is effective as additive treatment in mania.Other hypotheses are that virtual darkness therapy has significant effects on sleep, motor activity, circadian rhythm and mood also in the non-bipolar control-group.

NCT ID: NCT01541605 Completed - Mania Clinical Trials

Methylphenidate for the Treatment of Acute Mania

Start date: March 2012
Phase: Phase 3
Study type: Interventional

This study aims at evaluating the efficacy and safety of methylphenidate in the initial treatment of acute mania in patients with bipolar affective disorders.

NCT ID: NCT01315028 Completed - Mania Clinical Trials

Bipolar Intervention Study: Cognitive Interpersonal Therapy

BISCIT
Start date: November 2010
Phase: N/A
Study type: Interventional

There is a need to develop a better understanding of the early phase of bipolar disorder, and to develop and evaluate effective psychosocial interventions that assist people in this phase. The purpose of this study is to determine whether or not it is feasible to conduct a larger study of the effectiveness of cognitive interpersonal therapy (a psychological therapy) with individuals who have experienced their first or second treated episode of mania or hypomania (symptoms common in early development of bipolar disorders).

NCT ID: NCT01272518 Recruiting - Depression Clinical Trials

Assessment of Cardiac Autonomic Behavior in Patients With Mood Disorders

Start date: January 2011
Phase:
Study type: Observational

The purpose of this study is to characterize the behavior of cardiac patients with Mood Disorders and its clinical course, interpreting the results from a theoretical framework of Chaos Theory and Complexity Theory and Systems as well.

NCT ID: NCT01237379 Completed - Bipolar Disorder Clinical Trials

Peroxisomal Defects and Familial Risk for Bipolar Disorder

Start date: October 2010
Phase: N/A
Study type: Observational

The purpose of this study is to screen for peroxisome defects in child and adolescent offspring of Bipolar Disorder I (BD-I) parents at different stages of risk for transitioning to mania and following the onset of mania. Prediction 1: Youth with an elevated risk for developing BD-I and first-episode manic patients will exhibit graded deficits in measures of peroxisomal function compared with healthy controls. Prediction 2: Indices of peroxisomal function will be correlated with Red Blood Cells Docosahexaenoic acid (DHA) composition. Prediction 3: Graded deficits in measures of peroxisomal function will be inversely correlated with manic and depression symptom severity scores.

NCT ID: NCT01191918 Completed - Bipolar Disorder Clinical Trials

The Efficacy and Safety of AChE Inhibitor Donepezil As Adjunctive Treatment to Mood Stabilizers in Acute Mania

Start date: May 2005
Phase: Phase 4
Study type: Interventional

There is a high rate of partial response to standard thymoleptic medication. In this study the investigators want to evaluate the safety and efficacy of donepezil as adjunctive treatment to mood stabilizers in bipolar disorder with acute mania. The investigators hypotheses were that there would be greater mean reduction in manic symptoms with donepezil augmentation of lithium compared with placebo.